Exploring HER2 In Breast Cancer Treatment Responsiveness
Links shared publicly online about this topic.
- 387total visits
Exploring HER2 In Breast Cancer Treatment Responsiveness
View full resource at medicalnewstoday.com
Tags: Cancer, Breast Cancer, Women's Health
Most Recently Shared on April 5, 2011 at 8:05 pm By:
Exploring HER2 In Breast Cancer Treatment Responsiveness http://mnt.to/3Tdc #breastcancer
Oncology Article | Breast Neoplasms
mdlinx.com — “Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer” View full resource at mdlinx.com
Most Recently Shared on May 6, 2011 at 6:35 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-posi... http://bit.ly/lYQTBh #oncology
Exploring HER2 in Breast Cancer Treatment Responsiveness
newswise.com — “Research from New Jersey--™s only NCI-Comprehensive Cancer Center explores the protein HER2 and the role it plays in breast cancer aggressiveness, poor clinical outcome and chemotherapy resistance. The findings, being presented at the 102 Annual Meeting of the AACR, indicate that under stressful conditions, too much HER2 can cause a decrease in the cell-survival mechanism of autophagy. This decrease can lead to the alteration of other cellular processes and may increase breast cancer metas” View full resource at newswise.com
Most Recently Shared on April 5, 2011 at 5:46 pm By:
#health news: Exploring HER2 in Breast Cancer Treatment Responsiveness: Research from New Jersey's only NCI-Comp... http://bit.ly/fscAGN
Phase III Efficacy Data on Bevacizumab Plus Chemotherapy in Early Breast Cancer to be Presented
newswise.com — “1) Possible new treatment option for early HER2-negative breast cancer; 2) Safety data, published earlier this year, indicated bevacizumab was feasible; 3) Data on response and surgical outcomes to be presented at symposium.” View full resource at newswise.com
Most Recently Shared on December 10, 2010 at 11:34 pm By:
newswise Health Communicator and Health News
Phase III Efficacy Data on Bevacizumab Plus Chemotherapy in Early Breast Cancer to be Presented: 1) Possible new... http://bit.ly/gbzhWa
Genentech announces positive results from Phase II study of T-DM1
news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.” View full resource at news-medical.net
Most Recently Shared on December 14, 2009 at 6:52 am By:
Genentech announces positive results from Phase II study of T-DM1: Genentech, Inc., a wholly owned member of the Ro... http://bit.ly/5lngSQ
BBC Superhuman - The Enemy Within (Cancer) • VideoSift: Online Video *Quality Control
videosift.com — “This episode deals with cancer. What is cancer and how it is presently being treated is elaborated with the help of four patients undergoing different treatments. Iceland's sad fact of having the highest rates of breast and prostate cancer is also explored. "One in three of us will develop cancer and many will die from it. In response, medicine is making dramatic advances in the treatment of the disease which include the use of the poisonous African bush willow plant and gene therapy whereb” View full resource at videosift.com
Most Recently Shared on August 18, 2009 at 5:50 am By:
VIDEO episode from SUPERHUMAN, 'The Enemy Within - #Cancer." New research into causes, new treatments http://bit.ly/QGGRw
Advertisement
